- Predictive
Oncology is at forefront of growing trend of precision medicine
- The
company applies smart tumor profiling, AI platform to extensive genomic
and biomarker patient data sets
- POAI
has large amounts of historical, standardized patient data from clinical
testing that can be leveraged immediately
The moment has come for Predictive
Oncology Inc. (NASDAQ: POAI). A knowledge-driven, precision-medicine
company, POAI focuses on applying data and artificial intelligence to
personalized medicine and drug discovery. The company applies its smart tumor
profiling and AI platform to extensive genomic and biomarker patient data sets
to predict clinical outcomes and, most importantly, improve clinical outcomes
for cancer patients of today and tomorrow.
While precision medicine, sometimes referred to as
personalized medicine, is a relatively new term, the idea has been around for
years (http://ibn.fm/KlNJH).
Defined by the U.S. National Library of Medicine as “an emerging approach for
disease treatment and prevention that takes into account individual variability
in genes, environment, and lifestyle for each person,” the approach is gaining
momentum as data sets especially in genomics have grown rapidly. Applying AI
approaches to these large data sets offers the ability to more deeply analyze
these data much faster and with more accurate results than previously.
Predictive Oncology is at the forefront of this growing
trend that examines multiple factors about the patient from genomics, tumor
profiles, nutrition, environmental factors, lifestyle and habits to determine a
plan of action for treatment. In a recent overview (http://ibn.fm/pYVQI), POAI notes
that for years, big pharma has invested tremendous resources — both financial
and human — in genomics in order to understand a patient’s genome and hopefully
provide more targeted treatments. However, despite the significant amount of
time and money devoted to the research, success rates for such targeted
therapies remain low, and adoption in clinical practice is lukewarm. It has
become increasingly clear that genomics alone is not enough.
Experts are beginning to see a compelling need for a
multi-omic approach, or a method that combines a variety of data sets including
genome, transcriptome, epigenome, proteome, response-ome and microbiome.
However, while this approach may provide a higher chance of successful
treatment, accessing the data is proving to be challenging. Few comprehensive,
multi-omic data sets exist, and initiating new data-collection projects are
both time consuming and costly.
Enter Predictive Oncology. Competitors in the cancer field
must wait at least five years to determine patient survival rates for specific
treatments before they can show value in the data they have gathered. POAI, on
the other hand, has vast amounts of historical data that it has been compiling
for years, time-tested and proven data that can be leveraged today.
The company’s data includes two unique assets:
- A
clinically validated, patient-derived (PDx), tumor-profiling platform that
can generate drug-response profiles and other multi-omic data
- Data
on the drug-response profiles of more than 150,000 tumors across 137
cancer types, validated by using the PDx platform in more than a decade of
clinical testing.
In addition, the company continues to generate more data
every day and has the ability to mine its existing assets to identify even more
outcome data.
Predictive Oncology, which began as a joint venture between
Skyline Medical and Helomics, is ideally positioned to harness the power of
artificial intelligence and work with the pharmaceutical, diagnostic, and
biotech industries to develop AI-driven predictive models of tumor drug response
to impact patient outcomes.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating
to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
